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Summary 
Human prion diseases are associated with a range of clinical presentations, and they are 
classified by both clinicopathological syndrome and etiology, with subclassification 
according to molecular criteria. Here, we describe updated procedures that are currently 
used within the MRC Prion Unit to determine a molecular diagnosis of human prion 
disease. Sequencing of the PRNP open reading frame to establish the presence of 
pathogenic mutations is described, together with detailed methods for immunoblot or 
immunohistochemical determination of the presence of abnormal prion protein in brain or 
peripheral tissues. 
 
Key Words: Bovine spongiform encephalopathy; Creutzfeldt–Jakob disease; fatal 
familial insomnia; Gerstmann–Sträussler–Scheinker disease; kuru; prion; prion disease; 
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disease. 
 
Introduction 
Prion diseases are fatal neurodegenerative disorders that include Creutzfeldt–Jakob 
disease (CJD), Gerstmann–Sträussler–Scheinker disease (GSS), fatal familial insomnia 
(FFI), kuru, and variant CJD (vCJD) in humans (1-4). Their central feature is the 
posttranslational conversion of host-encoded, cellular prion protein (PrPC), to an 
abnormal isoform, designated PrPSc (1, 5). Human prion diseases are biologically unique 
in that the disease process can be triggered through inherited germline mutations in the 
human prion protein gene (PRNP), infection (by inoculation, or in some cases by dietary 
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exposure) with prion-infected tissue or by rare sporadic events that generate PrPSc (1-3). 
Substantial evidence indicates that abnormal PrP isoforms are the principal, if not the 
sole, components of the transmissible infectious agent, or prion (1, 2, 5). The existence of 
multiple strains or isolates of prions, has been difficult to accommodate within a protein 
only model of prion propagation; however, considerable experimental evidence suggests 
that prion strain diversity is encoded within PrP itself and that phenotypic diversity in 
human prion diseases relates to differing physicochemical properties of abnormal PrP 
isoforms (5-12). Furthermore, the propagation of distinct abnormal PrP isoforms may be 
determined by the host genome (13-15). 
 
Human prion diseases are associated with a range of clinical presentations, and they are 
classified by both clinicopathological syndrome and etiology, with subclassification 
according to molecular criteria (3, 4, 16-18). Approximately 85% of cases occur 
sporadically as Creutzfeldt–Jakob disease (sporadic CJD) at a rate of one to two cases per 
million population per year across the world, with an equal incidence in men and women 
(2, 19, 20). Approximately 15% of human prion disease is associated with autosomal 
dominant pathogenic mutations in PRNP, and to date more than 40 mutations have been 
described (2, 18, 21, 22). These include insertions of between four and twelve extra 
repeats within the octapeptide repeat region between codons 51 and 91, a two-octapeptide 
repeat deletion (OPRD), and various point mutations causing missense or stop 
substitutions (Fig. 1). 
 
 4 
Although human prion diseases are transmissible diseases, acquired forms have, until 
recently, been confined to rare and unusual situations. The most frequent causes of 
iatrogenic CJD occurring through medical procedures have arisen as a result of treatment 
with growth hormone derived from human cadavers or implantation of dura mater grafts 
(23-25). Less frequent incidences of iatrogenic human prion disease have resulted from 
transmission of CJD prions during corneal transplantation, contaminated 
electroencephalographic electrode implantation, and surgical operations using 
contaminated instruments or apparatus (25). The most well-known example of acquired 
prion disease in humans is kuru, which was transmitted by cannibalism among the Fore 
and neighboring linguistic groups of the Eastern Highlands in Papua New Guinea (17, 
26-28). Remarkably, kuru demonstrates that incubation periods of infection with human 
prions can exceed 50 years (28). The appearance of vCJD in the United Kingdom from 
1995 onward (29), and the experimental confirmation that this is caused by the same 
prion strain as that causing bovine spongiform encephalopathy (BSE) in cattle (7, 14, 30, 
31), has led to widespread concern that exposure to the epidemic of BSE poses a distinct 
threat to public health in the United Kingdom and other countries (3, 32). The extremely 
prolonged and variable incubation periods of these diseases, particularly when crossing a 
transmission barrier (3, 33), means that it will be many years before the full consequences 
of human exposure to bovine prions can be predicted with confidence. In the meantime, 
significant numbers in the population may be incubating this disease (34) and pose a risk 
for transmitting infection to others via blood transfusion, blood products, tissue and organ 
transplantation, and other iatrogenic routes (32, 35-39).  
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Polymorphism at codon 129 of PRNP (Fig. 2) (encoding either methionine [M] or valine 
[V]) powerfully affects susceptibility to human prion diseases (20, 27, 40-44). About 
38% of northern Europeans are homozygous for the more frequent methionine allele, 
51% are heterozygous, and 11% homozygous for valine. Homozygosity at PRNP codon 
129 predisposes to the development of sporadic and acquired CJD (20, 27, 40-43), and is 
most strikingly observed in vCJD where all pathologically proven cases studied so far 
have been homozygous for codon 129 methionine of PRNP (3, 38, 44-46). One 
heterozygous patient thought clinically to have vCJD did not have an autopsy 
examination (47). Heterozygosity at codon 129 is thought to confer resistance to prion 
disease by inhibiting homologous protein-protein interactions essential for efficient prion 
replication while the presence of methionine or valine at residue 129 controls the 
propagation of distinct human prion strains via conformational selection (3, 5, 32, 45, 
46). 
 
The clinical presentation of human prion disease varies enormously, and there is 
considerable overlap observed between individuals with different disease etiologies (3, 
19, 22) and even in family members with the same pathogenic PRNP mutation (21, 22, 
48-52). Progressive dementia, cerebellar ataxia, pyramidal signs, chorea, myoclonus, 
extrapyramidal features, pseudobulbar signs, seizures, and amyotrophic features can be 
seen in variable combinations. Criteria used for diagnosis of human prion disease are 
available (3, 53), and definite diagnosis of sporadic and acquired prion disease relies 
upon neuropathological examination and the demonstration of abnormal PrP deposition 
in the central nervous system by either immunoblotting or immunohistochemistry. In the 
 6 
appropriate clinical setting , identification of a pathogenic PRNP mutation provides clear 
diagnosis of inherited prion disease and subclassification according to mutation; PRNP 
analysis is also used for presymptomatic genetic testing in affected families (3, 17, 18, 
22, 48, 54, 55). Because of the extensive phenotypic variability seen in inherited prion 
disease and its ability to mimic other neurodegenerative conditions, notably Alzheimer’s 
disease, PRNP analysis should be considered in all patients with undiagnosed dementing 
and ataxic disorders (3, 22, 49). In addition, we have recently described a novel clinical 
and pathological phenotype associated with a Y163X mutation in PRNP, a prion protein 
systemic amyloidosis, characterised by slow disease progression, diarrhoea, autonomic 
failure and neuropathy (56). This newly recognised novel disease phenotype indicates 
that PRNP analysis should also be considered in the investigation of unexplained chronic 
diarrhoea associated with a neuropathy or an unexplained syndrome similar to familial 
amyloid polyneuropathy.  
 
Clinicians are fortunate that a range of sensitive and specific investigations are available 
to secure a diagnosis in life. Principal amongst these is magnetic resonance imaging 
(MRI) of the brain which shows increased signal on T2 or diffusion weighted images in 
the cerebral cortex, basal ganglia and thalamus in >80% of patients with sporadic CJD 
(57, 58), although these are sometimes overlooked (59). Cerebrospinal fluid (CSF) 
analysis is also helpful for differential diagnosis as the absence of a raised cell count or 
oligoclonal bands are reassuring from the point of view of inflammatory aetiologies. 
Raised CSF proteins 14-3-3, S100b and NSE are also found in ~90% sporadic CJD 
 7 
patients although their presence is not specific for the disease. CSF PrP amplification 
technologies show promise as specific and sensitive confirmatory tests (60, 61). 
 
The brains of patients with prion disease frequently show no recognizable abnormalities 
on gross examination at necropsy; however, microscopic examination of the brain at 
either necropsy or in ante-mortem biopsy specimens typically reveals characteristic 
histopathologic changes, consisting of neuronal vacuolation and degeneration, which 
gives the cerebral gray matter a microvacuolated or “spongiform” appearance 
accompanied by a reactive proliferation of astroglial cells (62-64). Although spongiform 
degeneration is frequently detected, it is not an obligatory neuropathologic feature of 
prion disease; astrocytic gliosis, although not specific to the prion diseases, is more 
constantly seen. The lack of a lymphocytic inflammatory response is also an important 
characteristic. Demonstration of abnormal PrP immunoreactivity, or more specifically 
biochemical detection of PrPSc in brain material by immunoblotting techniques is 
diagnostic of prion disease and some forms of prion disease are characterized by 
deposition of amyloid plaques composed of insoluble aggregates of PrP (62-65). Amyloid 
plaques are a notable feature of kuru and GSS (62, 65, 66), but they are less frequently 
found in the brains of patients with sporadic CJD, which typically show a diffuse pattern 
of abnormal PrP deposition (9, 62, 65). The histopathological features of vCJD are 
remarkably consistent and distinguish it from other human prion diseases, with large 
numbers of PrP-positive amyloid plaques that differ in morphology from the plaques seen 
in kuru and GSS in that the surrounding tissue takes on a microvacuolated appearance, 
giving the plaques a florid appearance (29, 67). The tissue distribution of PrPSc in vCJD 
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differs strikingly from that in classical CJD with uniform involvement of lymphoreticular 
tissues (35, 68-72). Depending upon the density of lymphoid follicles, PrPSc 
concentrations in vCJD peripheral tissues can vary enormously, with levels relative to 
brain as high as 10% in tonsil (35, 68) or as low as 0.002% in rectum (35, 39). Tonsil 
biopsy is used for diagnosis of vCJD, and to date it has shown 100% sensitivity and 
specificity for diagnosis of vCJD at an early clinical stage (3, 35, 38, 68), although some 
patients show scanty deposition of abnormal PrP and a large number of follicles may 
have to be examined by immunohistochemistry (73). 
 
In this chapter, we update our previous contribution to Prion Protein Protocols (74) and 
describe the procedures that are currently used within the MRC Prion Unit to provide a 
molecular diagnosis of human prion disease. Methods for sequencing the PRNP open 
reading frame to establish the presence of pathogenic mutations and to determine PRNP 
polymorphic codon 129 genotype are described together with procedures used for 
immunoblot or immunohistochemical determination of the presence of abnormal PrP in 
brain or peripheral tissues.  
 
2. Materials 
2.1. Molecular Genetics 
1. BACC3 DNA extraction kit from GE Healthcare Life Sciences. 
2. TE buffer: 10 mM Tris and 1 mM EDTA, pH 8.0. 
3. MegaMix Royal (Microzone, Haywards Heath, UK). 
4. HyperLadder 100bp (Bioline, London, UK). 
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5. MicroClean (Microzone). 
6. BigDye version 1.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA). 
7. BetterBuffer (Microzone). 
8. 0.5 M EDTA, pH 8.0, diluted fourfold in water. 
9. Hi-Di formamide (Applied Biosystems). 
10. Performance-optimized polymer 7 (Applied Biosystems). 
11. DdeI restriction endonuclease, including NEBuffer 3 (New England Biolabs, Ipswich, 
MA). 
12. MetaSieve agarose (Flowgen, Ashby, Leicestershire, UK). 
13. PflFI restriction endonuclease, including NEBuffer 4 (New England Biolabs). 
14. BsaI restriction endonuclease, including NEBuffer 3 (New England Biolabs). 
15. TOPO TA cloning kit for sequencing (Invitrogen, Paisley, UK). 
16. Luria-Bertani (LB) broth. 
17. TaqMan GTXpress Master Mix (Life Technologies, Paisley, UK). 
18 TaqMan MGB probes (Life Technologies, Paisley, UK). 
 
2.2. Immunoblotting 
1. Dulbecco’s sterile phosphate-buffered saline (PBS) lacking Ca2+ and Mg2+ ions. 
2. Duall tissue grinders (Anachem Ltd., Luton, Bedfordshire, UK). 
3. Proteinase K (specific enzymatic activity ~30 Anson units/g) prepared as a stock 
solution of 1 mg/ml in water. 
4. Sodium dodecyl sulfate (SDS) sample buffer. 
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a. A stock concentrate of 2× SDS sample buffer [142 mM Tris, 22.72% (v/v) 
glycerol, 4.54% (w/v) SDS, and 0.022% (w/v) bromphenol blue] is prepared 
in water and titrated to pH 6.8 with HCl. 
b. This solution requires adjustment with reducing agent and proteinase K 
inhibitor immediately before use to produce 2× working SDS sample buffer. 
c. For preparation of 0.5 ml of 2× working SDS sample buffer, mix the 
following: 440 l of stock concentrate of 2× SDS sample buffer plus 20 l of 
2-mercaptoethanol plus 40 l of 100 mM 4-(2-aminoethyl)-benzene sulfonyl 
fluoride prepared in water. 
d. This produces 2× working SDS sample buffer of the following final 
composition: 125 mM Tris-HCl, 20% (v/v) glycerol, pH 6.8, containing 4% 
(w/v) SDS, 4% (v/v) 2-mercaptoethanol, 8 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, and 0.02% (w/v) bromphenol blue. 
5. Novex® 16% Tris-glycine SDS-polyacrylamide gel electrophoresis (PAGE) gels (Life 
Technologies Ltd, Paisley, UK). 
6. Seeblue prestained molecular mass markers (Life Technologies Ltd). 
7. SDS-PAGE electrophoresis buffer: 100 ml of 10× Tris-glycine, SDS concentrate [0.25 
M Tris, 1.92 M glycine, 1% (w/v) SDS (National Diagnostics, USA)] plus 900 ml water. 
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8. Immobilon P transfer membrane. 
9. Electroblotting buffer: 100 ml of 10× Tris-glycine concentrate [0.25 M Tris and 1.92 
M glycine (National Diagnostics, USA)], 700 ml of water, and 200 ml of methanol. 
10. PBST: 100 ml of 10× PBS concentrate (low in phosphate) (VWR, Lutterworth, UK), 
900 ml of water, and 0.5 ml of Tween-20. 
11. Anti-PrP monoclonal antibody 3F4 (Covance, Princeton, New Jersey). 
12. Goat anti-mouse IgG (fab-specific) alkaline phosphatase conjugate (absorbed with 
human serum proteins) (Sigma-Aldrich Poole, Dorset, UK). 
13. CDP-star chemiluminescent substrate (Life Technologies Ltd). 
14. Carestream Biomax MR film (Anachem Ltd). 
15. AttoPhos chemifluorescent substrate (Promega, Madison, WI). 
a. Mix 36 mg of Attophos substrate in 60 ml of Attophos buffer. 
b. Store as 3 ml aliquots at –20C. 
16. Sodium lauroylsarcosine (Merk Chemicals Ltd, Nottingham, UK). 
17. Benzonase (Benzon nuclease purity 1 [25 U/l], Merck Chemicals Ltd). 
18. Sodium phosphotungstic acid stock solution. 
a. Stock solution is 4% (w/v) sodium phosphotungstic acid containing 170 mM 
MgCl2 prepared in water, pH 7.4. 
b. For preparation of 10 ml of stock solution, add 0.4 g of sodium 
phosphotungstic acid and 0.35 g MgCl2∙6H2O to a 50 ml polypropylene tube 
and make to ~9 ml with water. 
c. The pH of this solution is acidic and needs to be titrated with 5 M NaOH to 
pH 7.4 before adjusting to a final volume of 10 ml with water. 
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d. On addition of NaOH, immediate formation of insoluble MgOH2 occurs that 
will redissolve on vortexing. 
e. Addition of 5 M NaOH followed by vortexing and measurement of pH needs 
to be done repetitively. 
f. For 10 ml of stock solution, addition of 360 l of 5 M NaOH will generate pH 
7.4. 
2.3. Immunohistochemistry 
 
2.3.1. Procurement 
1. 10% buffered formal-saline. 
2. Biopsy cassettes (R. A. Lamb, Eastbourne, UK). 
 
2.3.2. Prion Deactivation with Formic Acid 
1. Biopsy cassettes (R. A. Lamb). 
2. 98% formic acid. 
3. 2 M sodium hydroxide: 80 g of sodium hydroxide pellets in water to 1 liter. 
4. 10% buffered formal-saline. 
 
2.3.3. Tissue Processing 
1. 10% buffered formal-saline. 
2. Industrial methylated spirits (J.M. Loveridge Ltd., Southampton, UK), diluted in water 
to desired concentration. 
3. Xylene. 
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4. Pure paraffin wax (R A Lamb). 
 
2.3.4. Tissue Sectioning 
1. Microtome (Leica, Wetzlar, Germany). 
2. SuperFrost microscope slides (VWR, West Chester, PA). 
 
2.3.5. Tissue Staining 
1. Xylene. 
2. Absolute ethanol diluted in water to desired concentration. 
3. Harris hematoxylin (BDH). 
4. Acid alcohol: 1% HCl in absolute ethanol. 
5. Eosin Y solution 0.5%, aqueous (VWR). 
6. Pertex mounting medium (Cox Scientific Ltd, Kettering, UK.). 
7. Benchmark staining machine (Ventana Medical Systems, Illkirch CEDEX, France). 
8. Protease 1 (Ventana Medical Systems). 
9. Rabbit anti-glial fibrillary protein (Dako UK Ltd., Ely, Cambridgeshire, UK); antibody 
diluent (Ventana Medical Systems). 
10. IViewDAB detection kit (Ventana Medical Systems), containing an inhibitor solution 
(3% hydrogen peroxide) (4 min), universal biotinylated secondary antibody (10 min), 
streptavidin-horseradish peroxidase solution (10 min), 3,3-diaminobenzidine and 
hydrogen peroxide (20 min), copper solution (4 min). 
11. Hematoxylin (Ventana Medical Systems). 
12. Bluing reagent (Ventana Medical Systems). 
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13. Tris-EDTA-citrate buffer, pH 7.8: 2.1 mM Tris, 1.3 mM EDTA, and 1.1 mM sodium 
citrate. 
14. 98% formic acid. 
15. 10 mM sodium citrate buffer, pH 6.0: solution A: 10.5 g of citric acid in 500 ml of 
deionized water and solution B: 29.41 g of sodium citrate in 1000 ml of water. 
a. Add 18 ml of solution A to 82 ml of solution B, and then adjust to 1 liter final 
volume with water. 
16. Anti-PrP monoclonal antibody ICSM35 (D-Gen Ltd., London, UK). 
17. Protease 3 (Ventana Medical Systems). 
18. Superblock (Pierce Chemical, Rockford, IL). 
19. Prepared with methanol GPR and 30% hydrogen peroxide. 
 
20. Tris-buffered saline (TBS): 50 mM Tris, 145 mM NaCl, pH 7.6. 
a. For 1 liter of 10× stock, add 60.5 g of Trizma base and 84.7 g of sodium 
chloride to 800 ml of water. 
b. Adjust to pH 7.6 with 32.00 ml of concentrated HCl. 
c. Make to 1 liter final volume with water. 
d. Dilute 10× TBS to 1× concentration with water. 
21. 4 M guanidine thiocyanate. 
a. Add 472.64 g guanidine thiocyanate in water to a final volume of 1 
liter. 
22. Normal rabbit serum (Dako UK Ltd.). 
23. Biotinylated rabbit anti-mouse immunoglobulins (Dako UK Ltd.). 
24. Strept ABComplex/HRP Duet kit (Dako UK Ltd.). 
25. 3,3-diaminobenzidine tetrachloride. 
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a. Use at a final concentration of 25 mg in 100 ml of 1× TBS. 
3. Methods 
 
3.1. Molecular Genetics 
3.1.1. Isolation of Genomic DNA from Blood 
1. All procedures are performed within a class 1 microbiological safety cabinet situated 
within an ACDP level II containment laboratory with strict adherence to local rules of 
safe working practice. Informed consent for the analysis of a sample must be established 
before investigation. This may be obtained from the patient (or next of kin or other 
advocate in accordance with the Mental Capacity Act 2005 in the UK). For predictive 
testing, we expect evidence of appropriate genetic counselling before analysis. 
2. Genomic DNA is extracted from whole anticoagulated blood (typically from a 5-ml 
EDTA tube) by using the Nucleon BACC3 DNA extraction kit (see Subheading 2.1., 
item 1) following the manufacturer’s instructions. DNA concentrations are determined 
using a Nanodrop ND-1000 spectrophotometer, and adjusted to 200–250 ng/l in TE 
buffer (see Subheading 2.1., item 2). Concentrations are re-measured before dilution of 
DNA in TE buffer to a final concentration of 20 ng/l and storage at 4C. 
 
3.1.2. Sequencing of PRNP Open Reading Frame 
 
3.1.2.1. PCR of PRNP Open Reading Frame 
1. Prepare a premix of MegaMix Royal (a 2x concentrate, see Subheading 2.1., item 3) 
containing primers at 0.5 μM sufficient for 25-l reactions on a 96-well plate. PCR 
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primers used to amplify the open reading frame are 5′-CTA TGC ACT CAT TCA TTA 
TGC-3′ (forward) and 5′-GTT TTC CAG TGC CCA TCA GTG-3′ (reverse). Use 12.5 l 
MegaMix Royal and make each reaction up to 25 l using water and primers. 
2. Add 1 l of 20 ng/l genomic DNA. 
3. Thermal cycling is performed on an MJ Research (Watertown, MA) Tetrad 1 PCR 
machine or similar using the following cycling parameters: 
a. 95 C for 5 min. 
b. 95 C for 30 s. 
c. 58 C for 40 s. 
d. 72 C for 1 min. 
e. repeat steps b–d an additional 34 times. 
 
4. Assess polymerase chain reaction (PCR) by electrophoresis of 5 l of product on a 2% 
ethidium bromide-stained agarose gel with 5 l of HyperLadder IV (see Subheading 
2.1., item 4) size standard. The gel is viewed using a Gel Doc 1000 transilluminator (Bio-
Rad, Hemel Hempstead, UK) and Quantity One 4.5.1 software or similar. 
 
3.1.2.2. PCR Product Cleanup 
1. An equal volume of MicroClean (see Subheading 2.1., item 5) 
is added to the PCR product and mixed well by pipetting or vortexing. 
2. The mixture is left at room temperature for 15 min. 
3. The plate is centrifuged at 2,000–4,000g for 40 min at room temperature. 
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4. The supernatant is removed by centrifuging the plate at 40g for 30 s in an inverted 
position on tissue paper by using centrifuge plate holders. 
5. Resuspend the cleaned PCR product in 150 l of water. 
 
3.1.2.3. Sequencing Reactions 
1. For each sequencing reaction, prepare a premix of 1 l of BigDye (see Subheading 
2.1., item 6), 5 l of BetterBuffer (see Subheading 2.1., item 7), 0.75 l of sequencing 
primer at 5 pmol/l, approximately 2.5 ng of cleaned PCR product, and water to a final 
volume of 15 l. The amount of PCR product is estimated using visual comparison with 
known amounts of HyperLadder IV (see Subheading 2.1., item 4) size standard. 
2. Sequencing primers are 5′-GAC GTT CTC CTC TTC ATT TT-3′ (forward 1), 5′-CCG 
AGT AAG CCA AAA ACC AAC-3′ (forward 2), and 5′-CAC CAC CAC TAA AAG 
GGC TGC-3′ (reverse 1), 5′-TTC ACG ATA GTA ACG GTC C-3′ (reverse 2). 
3. Sequencing reactions are thermally cycled on an MJ Research Tetrad 1 PCR machine 
or similar using the following cycling parameters: 
a. 96C for 1 min. 
b. 96C for 10 s. 
c. 50C for 5 s. 
d. 60C for 4 min. 
e. Repeat steps b–d 24 times. 
 
 
3.1.2.4. Sequencing Product Cleanup 
 18 
1. To each sequencing reaction, add 3.75 l of 0.125 M EDTA, pH 8.0 (see Subheading 
2.1., item 8). 
2. Add 45 l of 100% ethanol to each reaction and mix by pipetting. 
3. Leave reactions at room temperature for 15 min. 
4. Centrifuge the plate at 3,000g for 30 min at 4C. 
5. The supernatant is removed by centrifuging the plate at 185g for 1 min in an inverted 
position on tissue paper. 
6. Add 50 l of 70% ethanol in water. 
7. Centrifuge the plate at 1,650g for 15 min at 4C. 
8. The supernatant is removed by centrifuging the plate at 185g for 1 min in an inverted 
position on tissue paper. 
9. Place the plate on the PCR block held at 37C for 5 min to remove final traces of 
ethanol. 
 
3.1.2.5. Electrophoresis 
1. Add 10 l of Hi-Di formamide loading solution (see Subheading 2.1., item 9) and 
vortex the plate for 30 s. 
2. Denature the samples by placing on the PCR block held at 95C for 2 min and then 
immediately transfer to ice. 
3. Standard run conditions are applied to electrophoresis of sequencing products on an 
Applied Biosystems 3730xl, using polymer POP7 (see Subheading 2.1., item 10), 50-cm 
arrays, and a standard run module with a sample injection time of 15 s. 
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3.1.2.6. Data Analysis 
1. Data analysis is performed using Applied Biosystems Seqscape software version 2.5. 
2. Analysis filter settings are adjusted to allow assembly of poor data due to insertions or 
deletions (maximum mixed bases 95%, maximum Ns 95%, minimum clear length bp of 
1, and minimum sample score of 1). 
3. Poor data or failed reactions are removed from projects by visual inspection of data. 
 
3.1.3. PCR Size Fractionation to Investigate Insertion or Deletion Variants 
 
1. Prepare a premix of Mega Mix Blue (see Subheading 2.1., item 3) containing primers 
at 0.5 M sufficient for 25-l reactions on a 96-well plate. PCR primers are 5′-GAC CTG 
GGC CTC TGC AAG AAG CGC-3′ (forward) and 5′-GGC ACT TCC CAG CAT GTA 
GCC G-3′ (reverse). 
 
2. Add 1 l of 20 ng/l genomic DNA. 
3. Thermal cycling is performed on an MJ Research Tetrad 1 PCR machine or similar 
using the following cycling parameters: 
a. 94C for 5 min. 
b. 94C for 30 s. 
c. 65C for 30 s. 
d. 72C for 1 min. 
e. Repeat steps b–d 34 times. 
f. 72C for 5 min. 
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4. Assess PCR by electrophoresis of 5 l of product on a 2% ethidium bromide-stained 
agarose gel with 5 l of HyperLadder IV (see Subheading 2.1., item 4) size standard. 
The gel is viewed using a Bio-Rad Gel Doc 1000 transilluminator and Quantity One 4.5.1 
software or similar. 
5. 1 OPRD and 6 OPRI controls are run on each gel (Fig. 3). 
 
3.1.4. Mutation Confirmation 
A second assay is performed to confirm the presence or absence of missense or stop 
mutations when a predictive genetic test is being carried out. PCR size fractionation, as 
described above, is sufficient in addition to sequencing when testing for insertion mutants 
in a predictive setting; however, unexpected or unknown insertion mutations may require 
cloning to confirm exact base pair composition. Examples of confirmatory assays used to 
detect the more common PRNP missense mutations and cloning methodology are 
described in Subheading 3.1.4.1. 
 
3.1.4.1. Confirmation of P102L 
1. Prepare a premix of MegaMix Blue (see Subheading 2.1., item 3) containing primers 
at 0.5 M sufficient for 25-l reactions on a 96-well plate. PCR primers are 5′-GAC CTG 
GGC CTC TGC AAG AAG CGC-3′ (forward) and 5′-GGC ACT TCC CAG CAT GTA 
GCC G-3′ (reverse). 
2. Add 1 l of genomic DNA at 20 ng/l. 
3. Thermal cycling is performed on an MJ Research Tetrad 1 PCR machine or similar 
using the following cycling parameters: 
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a. 94C for 5 min. 
b. 94C for 30 s. 
c. 65C for 30 s. 
d. 72C for 1 min. 
e. Repeat steps b–d 34 times. 
f. 72C for 5 min. 
4. Prepare restriction endonuclease reaction by adding 10 l of PCR product, 1 l of 
DdeI (see Subheading 2.1., item 11), 2.5 l of 10× NEBuffer 3 (see Subheading 2.1., 
item 11), and 11.5 l of H2O. 
5. Incubate reaction at 37C for 3 h. 
6. Electrophorese 10 l of digested PCR product on a 3% 2:1 MetaSieve agarose (see 
Subheading 2.1., item 12) ethidium bromide-stained gel using 5 l of HyperLadder IV 
(see Subheading 2.1., item 4) size standard. The gel is viewed using a Bio-Rad Gel Doc 
1000 transilluminator and Quantity One 4.5.1 software. 
7. Digested positive and negative controls are run on each gel to visualize mutant DNA 
(95-, 101-, and 152-bp) and wild-type DNA (101- and 247-bp) fragment patterns. 
 
3.1.4.2. D178N 
1. Prepare a premix of MegaMix Blue (see Subheading 2.1., item 3) containing primers 
at 0.5 M sufficient for 25-l reactions on a 96-well plate. PCR primers are 5′-CTA TGC 
ACT CAT TCA TTA TGC-3′ (forward) and 5′-GTT TTC CAG TGC CCA TCA GTG-3′ 
(reverse). 
2. Add 1 l of genomic DNA at 20 ng/l. 
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3. Thermal cycling is performed on an MJ Research Tetrad 1 PCR machine or similar 
using the following cycling parameters: 
a. 94C for 5 min. 
b. 94C for 30 s. 
c. 55C for 40 s. 
d. 72C for 45 s. 
e. Repeat steps b–d 34 times. 
f. 72C for 5 min. 
4. Prepare restriction endonuclease reaction by adding 10 l of PCR product, 1 l of 
PflFI (see Subheading 2.1., item 13), 2.5 l of 10× NEBuffer 4 (see Subheading 2.1., 
item 13) and 11.5 l of H2O. 
5. Incubate reaction at 37C for 3 h. 
6. Electrophorese 10 l of digested PCR product on a 2% ethidium bromide-stained 
agarose gel by using 5 l of HyperLadder IV (see Subheading 2.1., item 4) size 
standard. The gel is viewed using a Bio-Rad Gel Doc 1000 transilluminator and Quantity 
One 4.5.1 software. 
7. Digested positive and negative controls are run on each gel to visualize mutant DNA 
(1015-bp) and wild-type DNA (386- and 629-bp) fragment patterns. 
 
3.1.4.3. E200K 
1. Prepare a premix of MegaMix Blue (see Subheading 2.1., item 3) containing primers 
at 0.5 M sufficient for 25-l reactions on a 96-well plate. PCR primers are 5′-CTA TGC 
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ACT CAT TCA TTA TGC-3′ (forward) and 5′-GTT TTC CAG TGC CCA TCA GTG-3′ 
(reverse). 
2. Add 1 l of genomic DNA at 20 ng/l. 
3. Thermal cycling is performed on an MJ Research Tetrad 1 PCR machine or similar 
using the following cycling parameters: 
a. 94C for 5 min. 
b. 94C for 30 s. 
c. 55C for 40 s. 
d. 72C for 45 s. 
e. Repeat steps b–d 34 times. 
f. 72C for 5 min. 
4. Prepare restriction endonuclease reaction by adding 10 l of PCR product, 1 l of BsaI 
(see Subheading 2.1., item 14), 2.5 l of 10× NEBuffer 3 (see Subheading 2.1., item 
14), and 11.5 l of H2O. 
5. Incubate reaction at 50C for 3 h. 
6. Electrophorese 10 l of digested PCR product on a 2% ethidium bromide-stained 
agarose gel by using 5 l of HyperLadder IV (see Subheading 2.1., item 4) size standard 
and view using a Bio-Rad Gel Doc 1000 transilluminator and Quantity One 4.5.1 
software. 
7. Digested positive and negative controls are run on each gel to visualize mutant DNA 
(1015-bp) and wild-type DNA (318- and 697-bp) fragment patterns. 
 
3.1.5. Characterization of Insertion Mutations 
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3.1.5.1. Generation of Amplicon to Be Cloned 
1. Prepare a premix of MegaMix Blue (see Subheading 2.1., item 3) containing primers 
at 0.5 M sufficient for 25-l reactions on a 96-well plate. PCR primers are 5′-GAC CTG 
GGC CTC TGC AAG AAG CGC-3′ (forward) and 5′-GGC ACT TCC CAG CAT GTA 
GCC G-3′ (reverse). (Note that MegaMix Blue contains an enzyme that has 3-prime 
terminal adenosine triphosphate transferase activity that ensures that the amplicon has 
“A” overhangs to anneal to the “T” overhangs of the cloning vector). 
2. Add 1 l of genomic DNA at 20 ng/l. 
3. Thermal cycling is performed on an MJ Research Tetrad 1 PCR machine or similar 
using the following cycling parameters: 
a. 94C for 5 min. 
b. 94C for 30 s. 
c. 65C for 30 s. 
d. 72C for 1 min. 
e. Repeat steps b–d 34 times. 
f. 72C for 10 min. 
4. Electrophorese 5 l of PCR product on a 2% ethidium bromide-stained agarose gel by 
using 5 l of HyperLadder IV (see Subheading 2.1., item 15) size standard and view 
using a Bio-Rad Gel Doc 1000 transilluminator and Quantity One 4.5.1 software. 
5. To preserve the “A” overhangs, before cloning, carry out as little manipulation as 
possible and use fresh product. 
 
 25 
3.1.5.2. Ligation and Cloning 
1. Perform TOPO TA cloning as described in the online user manual version O, 10 April 
2006 (25-0276). Updates of this protocol are available at www.invitrogen.com. Use 
Invitrogen cat. no. K4575-01 (see Subheading 2.1., item 15) (TOP10, Chemically 
Competent E. coli, 20 reactions). 
 
3.1.5.3. Analysis and Sequencing of Recombinant Clones 
1. There is no need to miniprep possible positive clones. Pick white and light blue clones 
(color enhancement can be obtained by leaving the plate at 4C overnight if this is 
preferred) and inoculate wells of a prewarmed 96-well tissue culture or storage plate 
containing 150–200 l of LB broth (see Subheading 2.1., item 16) containing the 
appropriate antibiotic. 
2. Incubate at 37C for about 5–6 h or until the wells are opaque. 
3. Transfer 50-l aliquots to a 96-well PCR plate. 
4. Seal the plate and place on a PCR machine for 10 min at 99C to lyse the bacteria. 
Aliquots (1 l) of these crude DNA preparations can then be used to produce amplicons 
by using the same methods used to produce the original amplicon by simple transfer to a 
fresh 96-well PCR plate containing the appropriate PCR mix. 
5. Electrophorese 5 l of PCR product on a 2% ethidium bromide-stained agarose gel by 
using 5 l of HyperLadder IV (see Subheading 2.1., item 4) size standard. The gel is 
viewed using a Bio-Rad Gel Doc 1000 transilluminator and Quantity One 4.5.1 software. 
6. Amplicons from positive wells can be purified and sequenced according to the 
automated sequencing protocol for PCR products (see Subheadings 3.1.2.2.–3.1.2.6.). 
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7. Amplicons will contain Taq polymerase artefacts preserved in the cloning process. 
Therefore, at least three clones should be sequenced to obtain a consensus sequence, 
preferably on both strands. 
 
3.1.6 Alternative Confirmation of Missense or Stop Mutations using Real-Time PCR  
 
3.1.6.1 P102L 
1. For each reaction, prepare a premix of 10 l of GTXpress Master Mix (see 
Subheading 2.1., item 17), 2 l each of forward primer, reverse primer, wild-type probe 
and mutant probe and 1 l of water (Primer stocks at 9 M, probe stocks are at 2 M). 
Primer and probes are 5’-GGA GGT GGC ACC CAC AGT C-3’ (forward primer), 5’-
GCC ATG TGC TTC ATG TTG GTT-3’ (reverse primer), 5’-FAM-CTT ACT CGG 
CTT GTT C-3’ (wild-type probe) and 5’-VIC-CTT ACT CAG CTT GTT CC-3’ (mutant 
probe) (see Subheading 2.1., item 18). 
2. Add 1 l of genomic DNA at 20 ng/l. Positive, negative and no-template controls are 
also run on each plate. 
3. Thermal cycling and data capture are performed on a QuantStudio 12K Flex machine 
(Life Technologies) using a fast 96-well block, choosing genotyping mode and a fast 
instrument run. 
4. On completion of the run, inspecting the allele discrimination plot will show the 
unknown sample clustering with either the positive controls or the negative controls.  
 
3.1.6.2 D178N 
 27 
1. For each reaction, prepare a premix of 10 l of GTXpress Master Mix (see 
Subheading 2.1., item 17), 2 l each of forward primer, reverse primer, wild-type probe 
and mutant probe and 1 l of water. Primer and probes are 5’-CAG GCC CAT GGA 
TGA GTA CA-3’ (forward primer), 5’-CGT GTG CTG CTT GAT TGT GA-3’ (reverse 
primer), 5’-FAM-TTG ACG CAG TCG TGC A-3’ (wild-type probe) and 5’-VIC-TTG 
ACG CAG TTG TGC A-3’ (mutant probe) (see Subheading 2.1., item 18). 
2. Add 1 l of genomic DNA at 20 ng/l. Positive, negative and no-template controls are 
also run on each plate. 
3. Thermal cycling and data capture are performed on a QuantStudio 12K Flex machine 
(Life Technologies) using a fast 96-well block, choosing genotyping mode and a fast 
instrument run. 
4. On completion of the run, inspecting the allele discrimination plot will show the 
unknown sample clustering with either the positive controls or the negative controls.  
 
3.1.6.3 E200K 
1. For each reaction, prepare a premix of 10 l of GTXpress Master Mix (see 
Subheading 2.1., item 17), 2 l each of forward primer, reverse primer, wild-type probe 
and mutant probe and 1 l of water. Primer and probes are 5’-CGG TCA CCA CAA 
CCA CCA A-3’ (forward primer), 5’-CAC GCG CTC CAT CAT CTT AA-3’ (reverse 
primer), 5’-FAM-AAC TTC ACC GAG ACC GA-3’ (wild-type probe) and 5’-VIC-AGA 
ACT TCA CCA AGA CC-3’ (mutant probe) (see Subheading 2.1., item 18). 
2. Add 1 l of genomic DNA at 20 ng/l. Positive, negative and no-template controls are 
also run on each plate. 
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3. Thermal cycling and data capture are performed on a QuantStudio 12K Flex machine 
(Life Technologies) using a fast 96-well block, choosing genotyping mode and a fast 
instrument run. 
4. On completion of the run, inspecting the allele discrimination plot will show the 
unknown sample clustering with either the positive controls or the negative controls.  
 
3.2. Immunoblotting 
 
3.2.1. Biosafety 
1. All procedures are performed within a class 1 microbiological safety cabinet situated 
within an ACDP level III containment laboratory with strict adherence to local rules of 
safe working practice. Informed consent for the analysis of samples must be in place 
before investigation. 
2. No unsealed biological material (tissue or derivative sample thereof) is manipulated 
outside of the class 1 microbiological safety cabinet. Disposable gloves, safety gown, and 
safety glasses are worn at all times. 
3. 1.5-ml screw-top microfuge tubes containing a rubber O-ring are used. 
4. Guidelines for decontamination of human prions are available (75). All disposable 
plasticware (e.g., tubes, tips, and so on) and solutions containing biological material are 
decontaminated in 50% (v/v) sodium hypochlorite solution (containing >20,000 ppm 
available chlorine prepared in water) for at least 1 h before disposal of the liquid phase 
down designated laboratory sinks within the containment laboratory. Sharps (needles and 
scalpels) are disposed of immediately after use into a sharps bin and autoclaved at 136°C 
for 20 min before incineration. 
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5. Decontaminated plasticware is transferred to a sharps bin and autoclaved at 136°C for 
20 min before incineration. 
 
3.2.2. Preparation of Tissue Homogenate 
1. Tissue specimens, stored frozen in sealed pots within the ACDP level III containment 
laboratory, are transferred into a class 1 microbiological safety cabinet and partially 
thawed and placed on a petri dish. 
2. A suitable quantity of tissue is excised using a scalpel and sealed in a disposable 
plastic pot and weighed. The tissue is then prepared as a 10% (w/v) homogenate in 
Dulbecco’s sterile PBS lacking Ca2+ and Mg2+ ions (see Subheading 2.2., item 1). The 
amount of PBS to add in microliters is equal to 9 times wet weight of tissue in 
milligrams. This calculation will produce a homogenate very close to a true 10% (w/v) 
ratio without the necessity of having to accurately measure the total volume of tissue in 
PBS before the homogenization process. 
3. Homogenization of brain tissue is achieved by serial passage of tissue through syringe 
needles of decreasing diameter (needle gauges 19, 21, 23, and 25). 
4. Homogenization of peripheral tissue is achieved through the use of glass Duall tissue 
grinders (see Subheading 2.2., item 2). 
5. The homogenate is stored as aliquots in 1.5 ml screw-top microfuge tubes at –80°C. 
 
3.2.3. Proteinase K Digestion and Electrophoresis 
1. 10% brain homogenate is thawed, thoroughly vortexed, and then centrifuged at 100g 
(800 rpm) for 1 min in a microfuge (see Note 1). 
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2. 20-l aliquots of the resultant supernatant are adjusted to a final concentration of 50 
g/ml proteinase (see Subheading 2.2., item 3) by addition of 1.05 l of a 1 mg/ml 
proteinase K stock solution (see Note 2). 
3. Samples are incubated at 37°C for 1 h, followed by centrifugation at 16,100g (13,200 
rpm) for 1 min in a microfuge. 
4. The digestion is terminated by resuspension of the sample with an equal volume (21 
l) of 2× working SDS sample buffer (see Subheading 2.2., item 4) and immediate 
transfer to a 100°C heating block for 10 min. 
5. Samples for analysis in the absence of proteinase K treatment are treated directly with 
an equal volume of 2× working SDS sample buffer (see Subheading 2.2., item 4) and 
heated similarly. 
6. All samples are centrifuged at 16,100g (13,200 rpm) for 1 min in a microfuge, 
thoroughly vortexed, and then recentrifuged 16,100g for 1 min before electrophoresis of 
the supernatant. 
7. 10 l of the supernatant is loaded on an Novex® 16% Tris-glycine polyacrylamide 
mini gel (see Subheading 2.2., item 5) (see Note 3). The remainder of the sample can be 
stored at –80°C. Then, 10 l of 1× working SDS sample buffer (prepared by mixing 2× 
working SDS sample buffer with an equal volume of water) should be added in any blank 
lane. Ten microliters of Seeblue prestained molecular mass markers (see Subheading 
2.2., item 6) is used to calibrate the gel. 
8. Gels are run at a constant voltage of 200 V for 80 min in SDS-PAGE running buffer 
(see Subheading 2.2., item 7) (see Note 3). 
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9. Gels are electroblotted (one gel per XCell II™ blot module (Novex®)) on to 
polyvinylidene difluoride membrane (see Subheading 2.2., item 8) in electroblotting 
buffer (see Subheading 2.2., item 9) at a constant voltage of 35 V for 2 h or 15 V 
overnight. Immobilon P membrane is soaked for 2 min in 100% methanol and then rinsed 
in electroblotting buffer immediately before use. 
 
3.2.4. High-Sensitivity Chemiluminescence (ECL) 
1. Blots are blocked with 5% (w/v) nonfat milk powder in PBST (see Subheading 2.2., 
item 10) for 1 h followed by brief rinsing with PBST. 
2. Blots are incubated with anti-PrP monoclonal antibody 3F4 (see Subheading 2.2., 
item 11) at a final concentration of 0.2 g/ml in PBST containing 0.1% (w/v) sodium 
azide for either 90 min or overnight. 
3. Blots are washed for a minimum of 30 min and up to 60 min with at least six changes 
of PBST. 
4. Blots are incubated for 1 h with a 1:10,000 dilution of goat anti-mouse IgG-
phosphatase conjugate (see Subheading 2.2., item 12) in PBST. 
5. Blots are washed for a minimum of 30 min and up to 60 min with at least six changes 
of PBST.  
6. Blots are washed 2 × 5 min with 20 mM Tris, pH 9.8, containing 1 mM MgCl2. 
7. Blots are developed with chemiluminescent substrate CDP-Star (see Subheading 2.2., 
item 13) and visualized on Biomax MR film (see Subheading 2.2., item 14) (see Note 
4). 
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3.2.5. Standard Enhanced Chemifluorescence (ECF) 
1. Blots are blocked with 5% (w/v) nonfat milk powder in PBST (see Subheading 2.2., 
item 10) for 1 h followed by brief rinsing with PBST. 
2. Blots are incubated with anti-PrP monoclonal antibody 3F4 (see Subheading 2.2., 
item 11) at a final concentration of 0.2 g/ml in PBST containing 0.1% (w/v) sodium 
azide for either 90 min or overnight. 
3. Blots are washed for a minimum of 30 min and up to 60 min with at least six changes 
of PBST. 
4. Blots are incubated for 1 h with a 1:5,000 dilution of goat anti-mouse IgG-phosphatase 
conjugate (see Subheading 2.2., item 12) in PBST. 
5. Blots are washed for a minimum of 30 min and up to 60 min with at least six changes 
of PBST. 
6. Blots are washed 2 × 5 min with 20 mM Tris, pH 9.8, containing 1 mM MgCl2. 
7. Blots are developed with chemifluorescent substrate AttoPhos (see Subheading 2.2., 
item 15) and visualized on a Storm 840 PhosphorImager (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK). PrP glycoforms are quantified with ImageQuaNT software (GE 
Healthcare) (see Note 4). 
 
3.2.6. Sodium Phosphotungstic Acid Precipitation 
Methods are adapted from the original procedure of Safar et al. (76) as described by 
Wadsworth et al. (35). 
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1. 10% (w/v) homogenates from human brain or peripheral tissues prepared in 
Dulbecco’s PBS lacking Ca2+ and Mg2+ ions (see Subheading 2.2., item 1) are 
centrifuged at 100g (800 rpm) for 1 min in a microfuge. 
2. 500 l of the resultant supernatant is mixed with an equal volume of 4% (w/v) sodium 
lauroylsarcosine (see Subheading 2.2., item 16) prepared in Dulbecco’s PBS lacking 
Ca2+ and Mg2+ ions (see Subheading 2.2., item 1) and incubated for 10 min at 37C with 
constant agitation. 
3. Samples are adjusted to final concentrations of 50 U/ml Benzonase (see Subheading 
2.2., item 17) (add 2 l of 25 U/l Benzon nuclease, purity 1) and 1 mM MgCl2 (add 0.5 
l of 2 M MgCl2 prepared in water) and incubated for 30 min at 37C with constant 
agitation. 
4. Samples are adjusted with 81.3 l of a sodium phosphotungstic acid stock solution (see 
Subheading 2.2., item 18) to give a final concentration in the sample of 0.3% (w/v) 
sodium phosphotungstic acid. This stock solution is pre-warmed to 37C before use, and 
both the sample and the stock solution should be at 37C upon mixing to avoid formation 
of insoluble magnesium salts. 
5. Samples are incubated at 37C for 30 min with constant agitation before centrifugation 
at 16,100g (13,200 rpm) for 30 min in a microfuge. The microfuge rotor can be 
prewarmed to 37C before use, because this helps to avoid salt precipitation during 
centrifugation. 
6. After careful isolation of the supernatant, the sample is recentrifuged at 16,100g 
(13,200 rpm) for 2 min, and the residual supernatant is discarded. New tops are placed on 
the microfuge tubes. 
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7. Pellets are resuspended to a 20-l final volume with Dulbecco’s PBS lacking Ca2+ and 
Mg2+ ions containing 0.1% (w/v) sodium lauroylsarcosine and proteinase K digested and 
processed for immunoblotting as described in Subheading, 3.2.3, steps 2-9 (see Note 5). 
 
3.3. Immunohistochemistry 
3.3.1. Procurement 
3.3.1.1. Biosafety 
For samples suspected to contain infectious prions, all procedures are performed within a 
class 1 microbiological safety cabinet situated within an ACDP level III containment 
laboratory with strict adherence to local rules of safe working practice. Informed consent 
for the analysis of samples must be in place before investigation. Samples are kept in a 
category III laboratory before decontamination with formic acid. Guidelines for 
decontamination of human prions are available (75). Liquids that have been in contact 
with infected samples are decontaminated by mixing with an equal volume of 2 M 
sodium hydroxide for at least 1 h. For certain reagents, specialist disposal is preferred due 
to chemical incompatibilities (75). 
 
3.3.1.2. Whole Brain, Brain Hemispheres, or Whole Internal Organs 
1. Large specimens of tissue (whole brain, brain hemispheres, whole internal organs) are 
suspended in 10% buffered formal-saline (see Subheading 2.3.1., item 1). The volume 
added should be approximately 5 times the volume of tissue. 
2. If there is excess blood within the sample, the 10% buffered formal-saline should be 
exchanged until it remains clear. 
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3. Tissue is left for up to 3 weeks to ensure adequate fixation and hardening. 
4. After fixation, samples of tissue are excised with dimensions suitable for histology 
cassettes (see Subheading 2.3.1., item 2). 
 
3.3.1.3. Small Specimens of Brain or Peripheral Tissues 
1. Smaller pieces of brain (frontal cortex, temporal cortex, parietal cortex, occipital 
cortex, cerebellum) or samples of other peripheral tissues (tonsil, spleen, lymph nodes, 
appendix), with dimensions no larger than approximately 3 cm × 3 cm × 1 cm, are 
commonly provided for investigation. 
2. Tissue samples are immersed in approximately 5 volumes of 10% buffered formal-
saline (see Subheading 2.3.1., item 1). 
3. If there is excess blood within the sample, the 10% buffered formal-saline should be 
exchanged until it remains clear. 
4. Fixation of the samples is achieved after 2 days. 
5. After fixation, samples of tissue are excised with dimensions suitable for histology 
cassettes (see Subheading 2.3.1., item 2). 
 
3.3.2. Prion Deactivation with Formic Acid 
1. All brain tissue must be of a size suitable for processing. Generally, this is considered 
as the size and thickness of the histology cassettes (see Subheading 2.3.2., item 1). Care 
must be taken not to overfill the cassettes, because this will result in poor processing and 
distortion. 
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2. After being encased in labeled cassettes, the samples are immersed in 98% formic acid 
(see Subheading 2.3.2., item 2) for 1 h. 
3. Formic acid is decanted into a waste pot half filled with 2 M sodium hydroxide (see 
Subheading 2.3.2., item 3). 
4. Specimens are treated with approximately5 volumes of 10% buffered formal-saline 
(see Subheading 2.3.2., item 4) for 1 h. 
5. The 10% buffered formal-saline (see Subheading 2.3.2., item 4) is exchanged at least 
once to ensure any excess of formic acid has been removed before tissue processing. 
6. Samples are removed from the ACDP level III containment laboratory. 
7. Samples are placed on a tissue processor in an ACDP level II containment laboratory. 
 
3.3.3. Tissue Processing 
10% buffered formal saline (see Subheading 2.3.3., item 1) is an aqueous fixative; 
therefore, the samples are treated through a series of processing stages before wax 
embedding. Each stage needs to be of sufficient length to ensure impregnation. The 
stages are as follows: 
1. Dehydration: The samples are taken through a series of industrial methylated spirits 
(IMS) (see Subheading 2.3.3., item 2) (70, 90, 100%) to remove water (Table 1). 
2. Clearing: The alcohol is replaced by xylene (see Subheading 2.3.3., item 3), a fluid 
miscible with IMS and paraffin wax (see Subheading 2.3.3., item 4) (Table 1). 
3. Impregnation: the xylene is replaced with molten paraffin wax (see Subheading 2.3.3., 
item 4) (Table 1). 
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4. Embedding: The samples are embedded in the desired orientation in molten paraffin 
wax (see Subheading 2.3.3., item 4). Once the wax has hardened, the samples are ready 
for sectioning. 
 
3.3.4. Tissue Sectioning 
1. The microtome (see Subheading 2.3.4., item 1) is set at 8 m for tissue sectioning, 
although this measure can be varied. 
2. The sample block, now in wax, is mounted on to the microtome chuck and serial 
sections of the sample are taken. 
3. Sections are floated out on a water bath set at 40C. 
4. The sections are mounted on SuperFrost microscope slides (see Subheading 2.3.4., 
item 2) and left to air dry at 37C for approximately 2 h. 
5. Slides are dried at 60C for a minimum of 2 h, after which they are ready to be stained. 
6. Tonsil sections require cutting just before staining. Immunoreactivity is markedly 
reduced if sections are exposed to air for long periods of time. 
 
3.3.5. Tissue Staining 
 
3.3.5.1. Staining with Hematoxylin and Eosin (H&E) 
1. Rehydrate the sections by removing paraffin in three changes of xylene (see 
Subheading 2.3.5., item 1), followed by sequential washing for 1–2 min with graded 
alcohol (see Subheading 2.3.5., item 2) (100% × 2, 90%, and 70%) and final washing in 
running tap water. 
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2. Place the slides in filtered Harris hematoxylin solution (see Subheading 2.3.5., item 3) 
for 5 min. 
3. Wash briefly in running tap water and differentiate in 1% acid alcohol (see 
Subheading 2.3.5., item 4) for 30 s. 
4. Wash well in running tap water and allow the color to develop. Check microscopically. 
Nuclei look dark blue, whereas background shows a weak residual hematoxylin 
coloration. 
5. Wash briefly in running water and stain with Eosin Y solution (see Subheading 2.3.5., 
item 5) for 2–3 min. 
6. Wash sections sequentially for ~1–2 min with water, 70% ethanol, 90% ethanol, 100% 
ethanol, and xylene. 
7. Mount sections in a xylene-based mounting medium, Pertex (see Subheading 2.3.5., 
item 6) (see Note 6). 
 
3.3.5.2. Staining for Glial Fibrillary Acidic Protein (GFAP) 
1. The sections to be stained are placed in plastic racks and paraffin removed, as 
described in Subheading 3.3.5.1. 
2. The slides are placed on the Benchmark XT Staining Machine (see Subheading 2.3.5., 
item 7) (Ventana Medical Systems) with a 4-min pre-treatment with Protease 1 (see 
Subheading 2.3.5., item 8). 
3. The slides are incubated with a GFAP antibody (see Subheading 2.3.5., item 9) 
diluted 1:1000 in antibody diluent (see Subheading 2.3.5., item 9). 
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4. The slides are stained using the staining kit IViewDAB (see Subheading 2.3.5., item 
10) and counterstained using hematoxylin (see Subheading 2.3.5., item 11) and a bluing 
reagent (see Subheading 2.3.5., item 12). 
5. Once the run is finished, the slides are washed in hot soapy water (diluted washing up 
liquid) and dehydrated through alcohol and xylene. 
6. Mount sections in a xylene-based mounting medium, Pertex (see Subheading 2.3.5., 
item 6) (see Note 7). 
 
3.3.5.3. Staining for PrP 
1. The sections to be stained are placed in plastic racks and paraffin removed as described 
in Subheading 3.3.5.1. 
2. The pre-treatment for detection of abnormal PrP deposition is dependent upon the 
tissue and the length of fixation. For human brain samples that have been fixed for up to 
~2 weeks, the microwave heat retrieval method is preferred. If the brain samples are fixed 
for longer periods, the pressure cooker method is used. If tonsil or other secondary 
lymphoid tissue is being examined, the autoclaving heat retrieval method is used. 
 
3.3.5.3.1. Microwave Method 
3. After removal of paraffin (see Subheading 3.3.5.1.) the slides are placed in 1 liter of 
Tris-EDTA-citrate buffer (see Subheading 2.3.5., item 13), and then they were placed in 
a microwave for 25 min at 800-W power. 
4. The slides are washed in running cold tap water for 3 min. 
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5. The samples are covered with 98% formic acid (see Subheading 2.3.5., item 14), 
incubated for 5 min, and then washed in running cold tap water for 5 min to remove 
excess formic acid. 
 
3.3.5.3.2. Pressure Cooker Method 
6. After removal of paraffin (see Subheading 3.3.5.1.), the slides are placed in a pressure 
cooker containing 1.5 liters of boiling Tris-EDTA-citrate buffer (see Subheading 2.3.5., 
item 13) for 5 min at high pressure and 5 min at low pressure. 
7. Place the slides under running cold water for 5 min and treat with 98% formic acid (see 
Subheading 2.3.5., item 14) for a further 5 min. Wash the slides in running water for 5 
min to remove excess formic acid. 
 
3.3.5.3.3. Autoclaving Heat Retrieval 
8. After removal of paraffin (see Subheading 3.3.5.1.), the slides are placed in an 
autoclave resistant tub containing 1 liter of citrate buffer (see Subheading 2.3.5., item 
15). 
9. The tub is covered with aluminium foil and run in an autoclave at 121°C for 20 min. 
Allow autoclave to return to low pressure before removing the tub. Place slides under 
running cold tap water. 
10. Treat with 98% formic acid (see Subheading 2.3.5., item 14) for a further 5 min. 
Wash the slides in running water for 5 min to remove excess formic acid. 
 
3.3.5.3.4. Automated Staining 
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11. The monoclonal anti-PrP antibody ICSM35 (see Subheading 2.3.5., item 16) (1 
mg/ml stock) is used at a 1:1,000 dilution in antibody diluent (see Subheading 2.3.5., 
item 9).  
12. Automated staining is carried out on the Benchmark Staining Machine (see 
Subheading 2.3.5., item 7) from Ventana Medical Systems. 
13. The slides are subjected to further pre-treatment with Protease 3 (see Subheading 
2.3.5., item 17) for 4 min, and then 10 min with Superblock (see Subheading 2.3.5., 
item 18), a blocking agent. The slides are stained using the staining kit IViewDAB (see 
Subheading 2.3.5., item 10) and counterstained using hematoxylin (see Subheading 
2.3.5., item 11) and a bluing reagent (see Subheading 2.3.5., item 12). 
14. Once the staining process is complete, the slides are washed in hot soapy water 
(diluted washing-up liquid) and dehydrated through alcohol and xylene. They are 
mounted in a xylene-based mountant as described in Subheading 3.3.5.1. (see Note 8). 
 
3.3.5.3.5. Manual Staining 
15. Sections are treated to remove paraffin as far as 100% alcohol (see Subheading 
3.3.5.1.). 
16. Block endogenous peroxidase activity on the sections by treatment with 2.5% (v/v) 
hydrogen peroxide in methanol (see Subheading 2.3.5., item 19) for 30 min. 
17. Wash sections in running tap water for 5 min and then in purified water for 5 min and 
transfer to an appropriate container for autoclaving. Autoclave at 121C for 20 min in 
Tris-buffered saline (TBS), pH 7.6 (see Subheading 2.3.5., item 20). 
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18. Cool slides in running tap water. Treat the slides in 98% formic acid (see 
Subheading 2.3.5., item 14) for 5 min, wash in running tap water for 5–10 min. 
19. Treat sections with 4 M guanidine thiocyanate (see Subheading 2.3.5., item 21) at 
4C for 2 h and then wash in tap water and transfer to TBS (see Subheading 2.3.5., item 
20). 
20. Block nonspecific immunoglobulin staining with normal rabbit serum (see 
Subheading 2.3.5., item 22) diluted 1:10 in TBS for 30 min. Do not wash off. 
21. Apply primary antibody ICSM35 (see Subheading 2.3.5., item 16) (1 mg/ml stock) 
at 1:1500 dilution in TBS containing 1:100 normal rabbit serum (see Subheading 2.3.5., 
item 22), overnight at 4C. 
22. Wash in several changes of TBS. 
23. Incubate in biotinylated rabbit anti-mouse immunoglobulins (see Subheading 2.3.5., 
item 23) 1:200 in TBS for 45 min. 
24. Wash in several changes of TBS. 
25. Incubate in ABC complex (see Subheading 2.3.5., item 24) for 45 min. 
26. Wash in several changes of TBS. 
27. Develop in 3,3 diaminobenzidine tetrachloride (see Subheading 2.3.5., item 25 (25 
mg/100 ml of TBS) plus 30 l of hydrogen peroxide (see Subheading 2.3.5., item 19) 
(added just before use) for 5–15 min. Check microscopically. Once chromogen has 
developed to satisfaction, wash slides in running tap water for 10 min. 
28. Counterstain in Harris hematoxylin (see Subheading 2.3.5., item 3) for 3 min. 
29. Differentiate in 1% acid alcohol (see Subheading 2.3.5., item 4) for 5 s. 
30. Allow blue coloration to develop in tap water, 5 min. 
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31. Dehydrate, clear, and mount as described in Subheading 3.3.5.1. (see Note 8). 
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4. Notes 
1. Whole brain homogenate can be analyzed by identical procedures; however problems 
of high sample viscosity due to nucleic acid aggregation are often encountered. For 
processing of 20 l of whole brain homogenate, preincubation with 0.5 l of Benzonase 
for 10 min at 20C is recommended before further sample analysis by using appropriately 
adjusted volumes of subsequent reagents. 
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2. PrPSc is covalently indistinguishable from PrPC, but it can by differentiated from PrPC 
by its partial resistance to proteolysis and its marked insolubility in detergents (1, 77). 
Under conditions in which PrPC is completely degraded by the nonspecific protease, 
proteinase K, PrPSc in sporadic and acquired forms of human prion disease exists in an 
aggregated form with the C-terminal two thirds of the protein showing marked resistance 
to proteolysis, leading to the generation of amino terminally truncated fragments of di-, 
mono- and nonglycosylated PrP (1, 77) (Fig. 4). 
3. The procedures described here have been optimized for use with Novex® 16% 
acrylamide precast Tris-glycine gels. Variation in the resolution of the system may occur 
if other gel systems are used or if reagent compositions are varied from those listed here. 
Optimal resolution of PrPSc fragment size is achieved after electrophoresis for 80 min at 
200 V. For improved separation of PrP glycoforms for densitometry analysis, 
electrophoresis is performed for 90 min at 200 V. 
4. To date, we have identified four major types of human PrPSc associated with sporadic 
and acquired human prion diseases that can be differentiated by their fragment size on 
immunoblots after limited proteinase K digestion of brain homogenates (7, 9, 78, 79) 
(Fig. 4). These types can be further classified by the ratio of the three PrP bands seen 
after protease digestion, corresponding to amino-terminally truncated cleavage products 
generated from di-, mono-, or nonglycosylated PrPSc (Figs. 4, 5). PrPSc types 1–3 are seen 
in classical (sporadic or iatrogenic) CJD brain, whereas type 4 PrPSc is uniquely seen in 
vCJD brain (7, 9, 78, 80). An earlier classification of PrPSc types seen in classical CJD 
described only two banding patterns (81) with PrPSc types 1 and 2 that we describe 
corresponding with the type 1 pattern of Gambetti and colleagues, and our type 3 
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fragment size corresponding to their type 2 pattern (8, 82). Although type 4 PrPSc is 
readily distinguished from the PrPSc types seen in classical CJD by a predominance of the 
diglycosylated PrP glycoform, type 4 PrPSc also has a distinct proteolytic fragment size 
(9) (Fig. 4), although this is not recognized by the alternative classification, which 
designates type 4 PrPSc as type 2b (82). Although proteinase K-resistant PrP fragments of 
~21–30 kDa seen in inherited prion disease caused by PRNP P102L, D178N, and E200K 
mutations have molecular masses similar in size to those seen in classical CJD (10, 83-
85), the glycoform ratio is distinct from PrPSc fragments seen in both classical CJD (10, 
83-85) and vCJD (10) (Fig. 5). Individuals with these mutations also propagate PrPSc 
with distinct fragment sizes (10, 83, 84). The fragment sizes and glycoform ratios of 
PrPSc seen in 2-, 4-, and 6-OPRI cases are indistinguishable from those of PrPSc seen in 
classical CJD (10). Importantly detection of PrPSc in the molecular mass range of ~21–30 
kDa is by no means a consistent feature in inherited prion disease; and some cases, in 
particular those in which amyloid plaques are a prominent feature, show smaller protease 
resistant PrP fragments of ~7–15 kDa derived from the central portion of PrP (10, 21, 83, 
84, 86-88) (Fig. 4). 
5. Sodium phosphotungstic acid precipitation facilitates highly efficient recovery and 
detection of PrPSc from human tissue homogenate, even when present at levels 104–105-
fold lower than found in brain (35, 89). This procedure is now the preferred method for 
diagnostic analysis of tonsil in cases of suspected vCJD, and it should detect PrPSc in 
tonsil if levels reach 0.1% or above the maximum levels seen in necropsy vCJD tonsil 
(35, 90). A distinctive PrPSc type, designated type 4t, is seen in both ante-mortem and 
post-mortem tonsil from patients with vCJD (35, 68) (see Figs. 5 and 7), including 
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secondary vCJD infection resulting from blood transfusion (38). Type 4t PrPSc in tonsil 
differs in the proportions of the PrP glycoforms from type 4 PrPSc seen in vCJD brain 
(35, 68) (see Figs. 5 and 7), implying the superimposition of tissue and strain specific 
effects on PrP glycosylation (32, 68). 
6. On H&E-stained sections nuclei are stained deep blue, and the cytoplasm is stained 
pink. The cortex and subcortical white matter can be readily distinguished. In the cortex 
of a patient with prion disease, there may be variable degrees of spongiosis, accompanied 
astroglial proliferation (Fig. 6). Neuronal loss also may be evident. Although synaptic 
PrP deposition is generally not recognizable on H&E sections, amyloid PrP plaques as 
seen in GSS and vCJD may be a prominent feature (Fig. 6). In the cerebellum, spongiosis 
is generally less evident; however, PrP plaques may be observed particularly in GSS. 
7. Reactive astrocytes are readily visualized by GFAP immunohistochemistry. They are 
characterized by prominent processes (Fig. 6). In the white matter, there may be a diffuse 
fibrillary gliosis. 
8. Abnormal PrP deposition can present with a multitude of intensities, shapes, and 
distributions. The synaptic pattern is characterized by a fine, dispersed distribution, and it 
is the predominant pattern of abnormal PrP staining seen in sporadic CJD (Fig. 6). In 
contrast, PrP amyloid plaques are a predominant feature in GSS, kuru, and vCJD. The 
histopathologic features of vCJD are remarkably consistent and distinguish it from other 
human prion diseases with large numbers of PrP-positive amyloid plaques that differ in 
morphology from the plaques seen in kuru and GSS in that the surrounding tissue takes 
on a microvacuolated appearance, giving the plaques a florid appearance (Fig. 6). 
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Abnormal PrP immunoreactivity in vCJD tonsil (38, 68, 90) and appendix (34, 91) is 
confined to lymphatic follicles with deposition mainly in dendritic cells (Fig. 7). 
 
Figure legends 
Fig. 1. Pathogenic mutations and polymorphisms in human prion protein. The pathogenic 
mutations associated with human prion disease are shown above the human PrP coding 
sequence. These consist of four to twelve OPRI within the octapeptide repeat region 
between codons 51 and 91, a two OPRD, and various point mutations causing missense 
or stop codon substitutions. Some of these changes have been observed in individual 
patients only and should be considered as possible pathogenic mutations that require 
confirmation. Point mutations are designated by the wild-type amino acid preceding the 
codon number, followed by the mutant residue, using single-letter amino acid 
nomenclature (X denotes stop). Polymorphic variants are shown below the PrP coding 
sequence (synonymous changes, green; nonsynonymous changes, blue). Codon 129 and 
219 polymorphisms have profound susceptibility, disease-modifying effects, or both. 
Deletion of one octapeptide repeat is not associated with prion disease in humans. 
 
Fig. 2. PRNP codon 129 polymorphism. Electropherogram traces that illustrate all PRNP 
codon 129 genotypes in the reverse DNA strand orientation. 
 
Fig. 3. Analysis of PRNP OPRI mutations. Image from agarose gel electrophoresis of 
PRNP amplicons illustrating the presence of an insertional mutation. Lane 1, 
HyperLadder IV; lane 2, 1-OPRD control; lane 3, 6 OPRI control; lane 4–8, patient 
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samples: lane 6 demonstrates amplification of a heterozygous insertional mutation of 144 
base pairs (6-OPRI mutation positive), lanes 4, 5, 7, and 8 are wild-type alleles only; lane 
9, no-template control. 
 
Fig. 4. Immunoblot analysis of human PrP. (A) Immunoblot analysis of normal human 
brain and vCJD brain homogenate before and after treatment with proteinase K (PK). 
PrPC in both normal and vCJD brain is completely degraded by PK, whereas PrPSc 
present in vCJD brain shows resistance to proteolytic degradation leading to the 
generation of amino terminally truncated fragments of di-, mono-, and nonglycosylated 
PrP. (B) Immunoblot of PK digested brain homogenate with monoclonal antibody 3F4 
showing PrPSc types 1–4 in human brain. Types 1–3 PrPSc are seen in the brain of 
classical forms of CJD (either sporadic or iatrogenic CJD), whereas type 4 PrPSc is 
uniquely seen in vCJD brain. Classification according to Hill et al. (9). (C) Immunoblots 
of PK digested brain homogenate from cases of inherited prion disease with PRNP 
mutations showing protease-resistant PrP fragments of ~6–8 kDa. The PRNP point 
mutation is designated above each immunoblot. Immunoblots were developed with anti-
PrP monoclonal antibody 3F4. 
 
Fig. 5. PrP glycoform ratios in human prion disease. PK digestion of brain homogenate 
and analysis by enhanced chemifluorescence with anti-PrP monoclonal antibody 3F4 
enables calculation of the proportions of di-, mono-, and nonglycosylated PrP. The plot 
shows the protease-resistant PrP glycoform ratio seen classical CJD (PrPSc types 1–3), 
vCJD (PrPSc type 4 in brain and type 4t PrPSc in tonsil) and in cases of inherited prion 
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disease. The key shows PrPSc type or mutation and PRNP codon 129 genotype 
(methionine [M] and valine [V]). Classification according to Hill et al. (9, 10). Data 
points represent the mean relative proportions of di- and mono-PrP as percentage ± 
S.E.M. In some cases the error bars were smaller than the symbols used. 
 
Fig. 6. Prion disease pathology. Brain sections from sCJD and vCJD show spongiform 
neurodegeneration after hematoxylin and eosin staining (H&E), proliferation of reactive 
astrocytes after immunohistochemistry using anti-GFAP antibodies (GFAP), and 
abnormal PrP immunoreactivity after immunohistochemistry using anti-PrP monoclonal 
antibody ICSM35 (PrP). Abnormal PrP deposition in sCJD most commonly presents as 
diffuse, synaptic staining, whereas vCJD is distinguished by the presence of florid PrP 
plaques consisting of a round amyloid core surrounded by a ring of spongiform vacuoles. 
Bar = 100 m. Inset, high-power magnification of a florid PrP plaque. 
 
Fig. 7. Abnormal PrP in vCJD tonsil and appendix. (A) Diagnostic PrPSc analysis of 
tonsil biopsy tissue. Aliquots (0.5 ml) of 10% (w/v) tonsil biopsy homogenate from a 
patient with suspected vCJD or 10% normal human tonsil homogenate, either lacking or 
containing a spike of 50 nl of 10% (w/v) vCJD brain homogenate, were subjected to 
sodium phosphotungstic acid precipitation. Then, 20 l aliquots of whole samples 
isolated before centrifugation were analyzed in the absence of PK digestion (–) and 
compared with PK digestion products (+) derived from the entire sodium 
phosphotungstic acid pellets. The immunoblot was analyzed with anti-PrP monoclonal 
antibody 3F4 and high-sensitivity enhanced chemiluminescence. (B) PK-digested sodium 
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phosphotungstic acid pellet derived from 0.5 ml 10 % (w/v) appendix homogenate from a 
patient with neuropathologically confirmed vCJD analyzed by high-sensitivity enhanced 
chemiluminescence using anti-PrP monoclonal antibody 3F4 (C). Immunohistochemical 
analysis of vCJD tonsil (i) and appendix (ii) obtained at autopsy. Abnormal PrP 
immunoreactivity is confined to lymphatic follicles with deposition mainly in dendritic 
cells. Anti-PrP monoclonal antibody ICSM 35. Bar = 160 m (C,i) and 100 m (C, ii). 
Insets, high-power magnification of PrP deposits. 
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Table 1 
Protocol for overnight processing of tissue samples for immunohistochemistry 
 
Solution Time (min) Temperature 
10% buffered formal-saline  30 Ambient 
IMS 70% 75 Ambient 
IMS 70% 75 Ambient 
IMS 70% 75 Ambient 
IMS 90% 60 Ambient 
IMS 90% 60 Ambient 
IMS 100% 75 Ambient 
IMS 100% 75 Ambient 
Xylene 75 Ambient 
Xylene 75 Ambient 
Molten paraffin wax 50 60C 
Molten paraffin wax 50 60C 
Molten paraffin wax 50 60C 
Molten paraffin wax 50 60C 
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